Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6565MR)

This product GTTS-WQ6565MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6565MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2673MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ6597MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ6813MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ9421MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ7278MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ3949MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ14299MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ11746MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-0646
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW